Compare GSL & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GSL | VOR |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | 2008 | 2021 |
| Metric | GSL | VOR |
|---|---|---|
| Price | $45.36 | $18.08 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $51.00 | $39.00 |
| AVG Volume (30 Days) | 246.0K | ★ 1.1M |
| Earning Date | 11-09-2026 | 11-12-2026 |
| Dividend Yield | ★ 5.66% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2.16 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.49 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $27.28 | $6.50 |
| 52 Week High | $46.57 | $39.49 |
| Indicator | GSL | VOR |
|---|---|---|
| Relative Strength Index (RSI) | 44.36 | 36.87 |
| Support Level | $37.00 | $11.62 |
| Resistance Level | $45.07 | $19.70 |
| Average True Range (ATR) | 0.93 | 1.23 |
| MACD | -0.28 | -0.37 |
| Stochastic Oscillator | 18.37 | 23.02 |
Global Ship Lease Inc is a containership owner, leasing ships to container shipping companies under industry-standard, fixed-rate time charters. Its fleet comprises mid-size Post-Panamax, Cypress, and smaller containerships, which tend to serve the faster-growing non-Mainlane and intra-regional trades, collectively representing the majority of the containerized trade volume globally. The company generates revenue from chartering its vessels to liner companies.
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.